The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 30% But Many Are Still Ignoring The Company

The Oncology Institute, Inc. (NASDAQ:TOI) shares have continued their recent momentum with a 30% gain in the last month alone. This latest share price bounce rounds out a remarkable 542% gain over the last twelve months.

Even after such a large jump in price, you could still be forgiven for feeling indifferent about Oncology Institute's P/S ratio of 0.7x, since the median price-to-sales (or "P/S") ratio for the Healthcare industry in the United States is also close to 1x. While this might not raise any eyebrows, if the P/S ratio is not justified investors could be missing out on a potential opportunity or ignoring looming disappointment.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

View our latest analysis for Oncology Institute

What Does Oncology Institute's Recent Performance Look Like?

Recent times have been advantageous for Oncology Institute as its revenues have been rising faster than most other companies. It might be that many expect the strong revenue performance to wane, which has kept the P/S ratio from rising. If not, then existing shareholders have reason to be feeling optimistic about the future direction of the share price.

Keen to find out how analysts think Oncology Institute's future stacks up against the industry? In that case, our free report is a great place to start.

Is There Some Revenue Growth Forecasted For Oncology Institute?

The only time you'd be comfortable seeing a P/S like Oncology Institute's is when the company's growth is tracking the industry closely.

Retrospectively, the last year delivered an exceptional 18% gain to the company's top line. The strong recent performance means it was also able to grow revenue by 92% in total over the last three years. Accordingly, shareholders would have definitely welcomed those medium-term rates of revenue growth.

Shifting to the future, estimates from the only analyst covering the company suggest revenue should grow by 19% over the next year. With the industry only predicted to deliver 8.7%, the company is positioned for a stronger revenue result.

With this information, we find it interesting that Oncology Institute is trading at a fairly similar P/S compared to the industry. Apparently some shareholders are skeptical of the forecasts and have been accepting lower selling prices.

The Bottom Line On Oncology Institute's P/S

Oncology Institute's stock has a lot of momentum behind it lately, which has brought its P/S level with the rest of the industry. Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

Looking at Oncology Institute's analyst forecasts revealed that its superior revenue outlook isn't giving the boost to its P/S that we would've expected. Perhaps uncertainty in the revenue forecasts are what's keeping the P/S ratio consistent with the rest of the industry. It appears some are indeed anticipating revenue instability, because these conditions should normally provide a boost to the share price.

We don't want to rain on the parade too much, but we did also find 4 warning signs for Oncology Institute (1 is potentially serious!) that you need to be mindful of.

If these risks are making you reconsider your opinion on Oncology Institute, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.